CA
NZ
UK
AU
IND
US
DarioHealth Corp. (NASDAQ: DRIO) has successfully raised approximately $23.5 million through a registered direct offering, comprising 2,437,060 shares priced at $6.80 each. This action marks a significant agreement disclosed by the company in recent months. The deal is expected to bolster the company’s cash …
Dyne Therapeutics, Inc. (NASDAQ: DYN) announced the pricing of an underwritten public offering. The offering consists of 18,300,000 shares of the Company’s common stock, each priced at $20.50. This pricing reflects a strategic decision to raise capital while offering an attractive entry point for …
Bluejay Diagnostics announced that the enrollment phase of its SYMON‑II multicenter clinical validation study achieved the predefined target of 750 participants earlier than anticipated. The Symphony™ IL‑6 platform is designed to deliver a bedside quantitative result within roughly 20 minutes, enabling clinicians to assess …
China Pharma Holdings (NYSE American: CPHI) completed a registered direct offering that will provide $5,000,000 of cash to the business. The transaction was executed on July 22, 2026, and settlement is expected shortly thereafter.
Community Health Systems Inc. For the quarter ending June 30, 2026, net operating revenues totalled $2.825 billion, reflecting a significant decline from $3.133 billion in the same period last year. The company's continued struggle with profitability is evident as it reported a net income …
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is undergoing a significant leadership transition as Ian T. Clark resigns from its board of directors, effective July 22, 2026. His departure comes after more than nine years of service, during which he contributed to the company's strategic direction …
20/20 Biolabs, Inc. (NASDAQ: AIDX) has secured a vital agreement with Streeterville Capital for a $40 million financing through the issuance of series E convertible preferred stock. This strategic move allows the company to bolster its financial resources amid a challenging market environment. The …
Today's session saw a broad, synchronized pullback across a group of major pharmaceutical and healthcare-distribution names, with declines ranging from roughly 0.5% to over 2%. Unlike a sharp trend reversal, the move reads more as a pause within otherwise constructive setups — McKesson (NYSE: …
Kairos Pharma, LTD. (NYSE American: KAPA) has announced a strategic collaboration with Bayer HealthCare Pharmaceuticals to further explore the therapeutic potential of its lead antibody, ENV-105 (carotuximab), in metastatic castration-resistant prostate cancer (mCRPC). This collaboration aims to bolster the treatment environment for prostate cancer, …
Hansa Biopharma AB's Q2 2026 earnings results showed a significant widening of losses, raising questions about its financial trajectory as it approaches a highly anticipated product launch. The company is focused on gearing up for entry into the market with its new product offering, …
Please wait processing your request...